Navigation Links
Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
Date:2/6/2012

HAMPTON, N.J., Feb. 6, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 14th Annual BIO CEO & Investor Conference.  Mr. Tasse's presentation will be given on Monday, February 13, 2012 at 3:30 p.m. EST in the Park South of the Waldorf Astoria in New York, NY.

About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com. Company Contact:Media Contacts:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372  

(212) 827-0020samina.bari@ikaria.comcsojda@tiberend.com 

 


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria® to Present at 2011 BIO Investor Forum
2. Ikaria® To Present at 2011 BIO Business Forum and International Convention
3. Cepheid to Webcast Upcoming Financial Presentations
4. Codexis to Present at the Pacific Crest and Jefferies Conferences
5. Life Technologies to Present at Upcoming Investment Conferences in February
6. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
9. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
10. LCA-Vision to Present at the Noble Financial Eighth Annual Equity Conference
11. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today that Scandinavian ... training plan management for consistent implementation of standards and regulatory requirements across SHL ... to help improve and streamline their training and employee development programs, which are ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Under ... years to develop a suite of BioGel™ biopolymer materials for hygiene applications, particularly ...
(Date:3/28/2017)... , Belgium , March 28, 2017 ... VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of ... DVD Associates, LLC, as a strategic consultant. Dr. Vollmer ... identifying and securing non-dilutive funding in the State ... United States . Dr. Vollmer Dahlke has ...
(Date:3/28/2017)... March 28, 2017 Biostage, Inc. ... developing bioengineered organ implants to treat cancers and other ... announced that Jim McGorry, CEO of Biostage, ... panel at the MassBio 2017 Annual Meeting ... ET in Cambrige, Massachussetts. The 3D Printing and ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
Breaking Biology News(10 mins):